View this email in your browser
scanning electron micrograph of microneedles

Pinpointing Solutions for Cancer Detection


Ovarian cancer is notoriously hard to detect. Lacking in reliable diagnostic or screening techniques and opaque in its biological origins, it is difficult to find or target until it has progressed to dangerously late stages. The Hammond and Irvine Labs, in conjunction with their clinical collaborators and a cohort of patients, are determined to change this.

Drawing on years of expertise in engineering, immunology, and materials chemistry, and on recent funding from the Bridge Project, a multi-disciplinary team of researchers has built a polymer microneedle patch that samples interstitial fluid in the body to screen for microRNAs from cancer cells. The patch, which also has applications for autoimmune diseases, could one day become the first noninvasive screening tool for ovarian cancer.


Read more »

Lindsay Case

A Case for Commendation


Congratulations to our newest extramural faculty member, biologist Lindsay Case, on being named a Searle Scholar. This annual award honors 15 outstanding U.S. assistant professors who have high potential for ongoing innovative research contributions in medicine, chemistry, or the biological sciences. Case studies the molecular mechanisms that lead to aberrant cell migration and signaling during cancer metastasis.


Read more »

dividing cells with a lysosomal marker on their surfaces

Spring Cleaning


Manalis Lab researchers have discovered that before cells divide, they take out the molecular trash using a process called lysosomal exocytosis. Because exocytosis plays a role in the development of resistance to some chemotherapies, the findings could inform new strategies for making cancer cells more susceptible to treatment. The study was published eLife and funded in part by the MIT Center for Precision Cancer Medicine.


Read more »

Two circular maps of cell lineages

Tumor Lineage: The Next Generation


A lineage-tracing collaboration between the Weissman, Jacks, and Yosef (UC Berkeley) labs boldly goes where far too many cells have gone before—from cancer-causing mutation to deadly tumor. Their CRISPR-enabled barcode technology allows them to track the evolution of cancer cells in unprecedented detail. The work was published in Cell and supported in part by the Ludwig Center at MIT.


Read more »

Daniel Zhang

Studying Cancer Across Continents


New MIT alum and aspiring MD/PhD student Daniel Zhang is headed to the Netherlands on a Fulbright scholarship. His planned project, developing an organoid co-culture system to study malignant rhabdoid tumors and screen for therapeutic vulnerabilities, builds on his longtime work in the Jacks Lab developing genetic knockout models for colorectal cancer.


Read more »

micrograph of cells permeated with lipid nanodiscs

Ultimate Frisbee


Substantial delivery challenges persist for agents that engage the STING pathway, a highly desirable cancer immunotherapy target. However, new tumor-penetrating lipid nanodiscs developed by the Irvine Lab outperformed previously designed nanoparticles in delivering STING-activating agents to induce tumor rejection and support immune memory against reintroduced tumor cells. This work was published in Nature Materials and supported in part by the Marble Center for Cancer Nanomedicine.

Becoming Bob


A new installment of the Bear Grylls Becoming X series features Bob Langer, who shares how he ended up in the chemical engineering field, how he eventually achieved his research goals, and how he’s put them to work in service of millions of people worldwide.


Watch now »

Diagram of unlooped, partially looped, and fully looped DNA

Thrown for a Loop


Human genomes are folded into loops that control important processes, such as gene expression and DNA repair, and may lead to cancer when misfolded. The Hansen Lab visualized loop formation—for the first time—and discovered that loops are more rare and short-lived than previously thought. The study, published in Science, illuminates the need for new models of how the genome’s 3D structure regulates cellular processes.


Read more »

conference attendees in coversation

With an AI Towards the Clinic


Regina Barzilay co-chaired the AI Cures conference for physicians and researchers interested in bringing artificial intelligence tools into the clinic. Fellow KI members Susan Hockfield and Phillip Sharp and Bridge Project collaborator Lecia Sequist were among those who attended the event, which was co-hosted by MIT and Mass General Brigham.


Read more »

micrograph of zebrafish skin cells

Beneath the Skin, More Than Meets the Eye


Lees Lab researchers probed the genetic underpinnings of cutaneous and uveal melanoma—cancers of pigment-producing cells found in the skin and eye, respectively. Their findings, published in PNAS, reveal key biological distinctions that can inform both clinical treatment development and broader understanding of how cancers of similar lineage develop in different tissue contexts.
natural killer cells

Dragonfly and Gilead Partnership Takes Flight
 

Immunotherapy startup Dragonfly, co-founded by KI member Tyler Jacks, announced a strategic research collaboration with pharmaceutical giant Gilead to advance their natural killer cell engager-based immunotherapies for cancer and inflammatory diseases. The partnership opens up broader pipelines for cancer drug development and approvals, and accelerates opportunities for patient impact and major distribution.


Read more »

Abstract image of dividing cells with text "10 years at the Koch Institute"

Register now for annual cancer research symposium on June 17

Future Founders Prize Competition participants

Future Founders Initiative hosts Prize Competition at the KI

Sangeeta Bhatia

Fierce Pharma names Sangeeta Bhatia among their “most influential”

molecule graphic

Daniel Anderson on what's next for RNA vaccines

Read more news
Give to the Koch Institute
Twitter
Facebook
Website
Copyright © 2022 Koch Institute for Integrative Cancer Research, All rights reserved.
You are receiving this email by request or because you opted in at our website.

Our mailing address is:
Koch Institute for Integrative Cancer Research
77 Massachusetts Avenue, 76-158
Cambridge, MA 02139

Add us to your address book


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.